Log In
Print this Print this

MVA-EBNA/LMP2 vaccine

  Manage Alerts
Collapse Summary General Information
Company Cancer Research UK
DescriptionVaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the Epstein-Barr virus (EBV) antigen Epstein-Barr nuclear antigen 1 (EBNA1) and fused to the EBV-associated antigen latent membrane protein 2 (LMP2)
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationNasopharyngeal cancer
Indication DetailsTreat EBV-positive nasopharyngeal carcinoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today